Lactoferrin efficacy in treating hyperferritinemia in patients suffering from pathologies unrelated to hereditary hemochromatosis
Biochemistry and Cell Biology · 2024
DOI: 10.1139/bcb-2024-0061 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Biochemistry and Cell Biology, 2024. Verfasst von Giuditta Pollio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ambulatorio di ematologia, Distretto 66, ASL Salerno, Salerno, Italy. Hauptthemen laut MEDLINE: Lactoferrin, Hemochromatosis, Hyperferritinemia. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Ferritin (Ftn), a globular protein, sequesters 4500 atoms of iron per molecule. Elevated serum Ftn levels (hyperferritinemia) is an indicator of iron homeostasis disorders. We present the results of an observational study involving 17 patients with hyperferritinemia unrelated to hereditary hemochromatosis (HH). All participants received treatment with 200 mg of bovine lactoferrin (bLf) once ( n = 14) or twice ( n = 3) a day before meals. The patients, treated with 200 mg/day of bLf, exhibited a significant increase in red blood cells (+10%, p < 0.001), hemoglobin (+4%, p < 0.001), and hematocrit (+15%, p = 0.004), accompanied by a significant reduction in serum Ftn levels (−52%, p < 0.001), C-reactive protein (CRP) (−85.0%, p < 0.001), and D-dimers (−19%, p < 0.001). Among the three patients treated with 400 mg/day of bLf, two had effects similar to those of patients bLf-treated with 200 mg/day and one experienced a strong reduction of Ftn, CRP, and erythrocyte sedimentation rate (from −97% to −75%). The decrease in serum Ftn levels due to bLf treatment was largely independent of gender ( p = 0.78), age ( p = 0.66), baseline symptoms ( p = 0.20), and concomitant acute ( p = 0.34) and chronic ( p = 0.53) infections. Although this observational pilot study yields positive effects in patients with hyperferritinemia unrelated to HH treated with bLf, a larger sample size is needed for conclusive results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ambulatorio di ematologia, Distretto 66, ASL Salerno, Salerno, Italy.
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
- Pharmaguida s.r.l., Rome, Italy.
- Microbo s.r.l., Rome, Italy.
- Clinical Epidemiology of Renal Diseases and Hypertension, Institute of Clinical Physiology (IFC), National Research Council (CNR), Ospedali Riuniti, Reggio Calabria, Italy.
ORCID-Profile: Luigi Rosa, Piera Valenti
Zitieren
APA
Pollio, G., Rosa, L., Costanzo, A. M., Paesano, R., Tripepi, G., & Valenti, P. (2024). Lactoferrin efficacy in treating hyperferritinemia in patients suffering from pathologies unrelated to hereditary hemochromatosis. Biochemistry and Cell Biology. https://doi.org/10.1139/bcb-2024-0061
Vancouver
Pollio G, Rosa L, Costanzo AM, Paesano R, Tripepi G, Valenti P. Lactoferrin efficacy in treating hyperferritinemia in patients suffering from pathologies unrelated to hereditary hemochromatosis. Biochemistry and Cell Biology. 2024. doi:10.1139/bcb-2024-0061
BibTeX
@article{Pollio2024,
author = {Pollio, Giuditta and Rosa, Luigi and Costanzo, Anna Maria and Paesano, Rosalba and Tripepi, Giovanni and Valenti, Piera},
title = {Lactoferrin efficacy in treating hyperferritinemia in patients suffering from pathologies unrelated to hereditary hemochromatosis},
journal = {Biochemistry and Cell Biology},
year = {2024},
doi = {10.1139/bcb-2024-0061}
}
EUVIMED